
Pharmacally
Ulcerative Colitis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Ulcerative Colitis
Health TidingsGilead Reports Positive Results for Emvistegrast in Ulcerative ColitisGilead’s investigational oral α4β7 integrin inhibitor emvistegrast met the Phase 2 SWIFT trial’s primary endpoint in moderately to severely active ulcerative colitis.Fact-Checked
Clinical TrialsSpyre’s SPY003 Delivers a Strong Phase 2 Signal in Ulcerative ColitisSpyre Therapeutics’ investigational anti-IL-23 antibody SPY003 significantly reduced histologic disease activity in moderately-to-severely active ulcerative colitis in the Phase 2 SKYLINE trial, supporting further development of the antibody…Fact-Checked
Health TidingsFDA Expands Stelara to Pediatric Ulcerative ColitisThe FDA approved Stelara (ustekinumab) for children aged 2 years and older with moderately to severely active ulcerative colitis, extending its use across both major forms of pediatric…Fact-Checked
Health TidingsAbivax Advances Obefazimod Toward FDA NDA for Ulcerative ColitisAbivax has completed a positive pre-NDA meeting with the U.S. FDA for obefazimod in moderately to severely active ulcerative colitis.Fact-Checked
Health TidingsDuvakitug Improves Clinical Remission in Ulcerative Colitis TrialPhase 2b results published in The Lancet Gastroenterology & Hepatology show that duvakitug, an investigational anti-TL1A monoclonal antibody from Teva and Sanofi, significantly increased clinical remission compared with…Fact-Checked
Clinical TrialsAbivax Reports Positive Phase 3 Maintenance Data for Obefazimod in Refractory Ulcerative ColitisAbivax announced topline results from ABTECT Maintenance Part 2, the supplemental Phase 3 study of obefazimod in ulcerative colitis.Fact-Checked
Clinical TrialsMerck’s Tulisokibart Shows Strong Phase 3 Efficacy in Ulcerative ColitisMerck reported positive Phase 3 results for tulisokibart in moderately to severely active ulcerative colitis.Fact-Checked
Clinical TrialsAbivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative ColitisAbivax has reported positive Phase 3 maintenance results for obefazimod in ulcerative colitis, with both 25 mg and 50 mg doses achieving significant clinical remission and broad efficacy…Fact-Checked
Clinical TrialsSpyre’s SPY001 Pushes the Boundary of UC Care with Promising Induction ResultsSPY001 met the primary endpoint in the Phase 2 SKYLINE trial, delivering significant histologic improvement along with strong remission and endoscopic response rates in ulcerative colitis patients.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.